“These trials look at the role of vision correction in powering not only better health outcomes for individuals, but in delivering sustainable development for countries around the world.”
Our story
DRIVE (Development and Research for International Vision correction and Equity) is the combination of eleven research trials, funded by the Chen Yet-Sen Family Foundation, Wellcome Trust, USAID, The MOH Foundation and Medical Research Council (UK). Together, they look at the role of vision correction in powering not only better health outcomes for individuals, but in delivering sustainable development for countries around the world.
The first DRIVE trial, PROSPER I, was completed in 2018 and proved that the productivity of a control group of tea-pickers in India significantly increased when provided with glasses to treat previously unaddressed sight problems.
A low-cost solution to a problem that impacts 2.2 billion people worldwide, the peer reviewed findings of PROSPER I helped to inform commitments from the Commonwealth Heads of Government and the United Nations, to back initiatives for universal affordable eyecare.
Focused on a range of demographics, from students at school and universities, to textile factory workers and older households, the next ten trials under the DRIVE umbrella – Bright Classrooms, CLEVER, PROSPER II, PROSPER III, STABLE, SWISH, THRIFT, ZEAL, SL2 and SL2 sub-study – will show that improving eyecare is both urgent and important for sustainable development.
The ultimate aim is not to deliver an invention, but to demonstrate that low-cost interventions exist and can be simply applied by policymakers to populations. In doing so, we believe they will improve education, literacy, productivity, financial independence, and mental and physical health.